Therefore, this study investigated whether luteolin could exert immunomodulatory effects, at near physiological concentrations when used alone or in combination with interferon beta (IFN-β) upon isolated PBMCs from MS patients. The gene discussed is IFNB1; the disease is myeloid sarcoma.